Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Deborah J. Kuhn,1 Sally A. Hunsucker,1 Qing Chen,2 Peter M. Voorhees,2 Marian Orlowski,3 Robert Z. Orlowski1,4

1Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston; 2Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston; 3Department of Pharmacology, Mount Sinai School of Medicine, New York, NY; and 4Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston

Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often associated with increasing chemoresistance. Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy. One novel approach may be to target the immunoproteasome, a proteasomal variant found predominantly in cells of hematopoietic origin that differs from the constitutive proteasome found in most other cell types. Using purified preparations of constitutive and immunoproteasomes, we screened a rationally designed series of peptidyl-aldehydes and identified several with relative specificity for the immunoproteasome. The most potent immunoproteasome-specific inhibitor, IPSI-001, preferentially targeted the βi subunit of the immunoproteasome in vitro and in cellulo in a dose-dependent manner. This agent induced accumulation of ubiquitin-protein conjugates, proapoptotic proteins, and activated caspase-mediated apoptosis. IPSI-001 potently inhibited proliferation in myeloma patient samples and other hematologic malignancies. Importantly, IPSI-001 was able to overcome conventional and novel drug resistance, including resistance to bortezomib. These findings provide a rationale for the translation of IPSIs to the clinic, where they may provide antmyeloma activity with greater specificity and less toxicity than current inhibitors. (Blood. 2009;113:4667-4676)

Introduction

The ubiquitin-proteasome pathway is used by eukaryotes as the major mechanism for regulated intracellular proteolysis. As such, it plays an important role in cellular homeostasis, and is critical to several processes, including angiogenesis, cell-cycle progression, DNA repair, programmed cell death, and the stress response.1,2 This pathway has become a validated target for cancer therapy with the approval of the proteasome inhibitor bortezomib as a single agent for mantle cell lymphoma3-5 and multiple myeloma (MM).6-8 Modulation of proteasome function is also a rational approach to achieve chemosensitization, and bortezomib with pegylated liposomal doxorubicin has recently been shown to be superior to bortezomib alone against MM.9 These successes have led to studies of the role of bortezomib in the up-front setting in myeloma, and to the introduction in early phase studies of a second generation of irreversible proteasome inhibitors, such as carfilzomib10 and NPI-0052.11,12

In its assembled form, the proteasome consists of a core 20S particle with 4 stacked rings of 7 subunits each. Most cells express the constitutive proteasome variant, in which the 20S core is capped on both ends by a 19S activator complex, which aids in stabilization, ATP-dependent removal of ubiquitin, and unfolding/shuttling of proteins into the core. The inner 2 rings contain β subunits numbered 1 through 7, of which β1, β2, and β5 participate in proteolysis.11-13 These encode the 3 major catalytic activities of the proteasome: chymotrypsin-like (ChT-L), trypsin-like (T-L), and post-glutamyl peptide hydrolyzing, or caspase-like (C-L) activities. One variant of the proteasome that has been described is the immunoproteasome, which differs from the constitutive proteasome in part through the replacement of β1, β2, and β5, with distinct subunits known as β1i, β2i, and β5i, to form the 20Si core.14,15 This variant, which also contains different regulatory subunits known as 11S or PA28,16 has been found to be highly expressed in cells of hematopoietic origin in several species.17-19 Studies of 20S, function have revealed that it generates peptide fragments with more hydrophobic and basic amino acids at the C-terminus,20 which are better suited for presentation to major histocompatibility class I molecules, providing the rationale for its name. However, the 20Si also participates in many constitutive proteolytic processes,17,19,21-24 and conversely the 20S proteasome may in some cases generate immunogenic epitopes,25 suggesting that each proteasome variant may provide both housekeeping and specialized functions.

The role that the 20S plays outside of the immune system is just beginning to be elucidated, with expression levels being correlated to several disease states, including Huntington disease,26 Alzheimer disease,27 and macular degeneration.28 Diseases associated with an aberrant immune response, such as inflammatory bowel disease29,30 and rheumatoid arthritis,31 have also been identified as having...
increased 20S expression. This may be due in part to the ability of inflammatory cytokines, such as tumor necrosis factor and interferon-γ, to induce expression and preferential incorporation of β1, β2, and β5 into the proteasome.16 Preferential expression of 20S has also been observed in MM,32 suggesting that specific immunoproteasome inhibition could be a promising therapeutic strategy. While bortezomib, carfilzomib, and NPI-0052, as well as other proteasome inhibitors, have been validated in myeloma and other model systems, all of these appear to target both the constitutive and immunoproteasomes indiscriminately. This lack of specificity may in part explain some of the side effects of these agents, such as peripheral neuropathy and gastrointestinal effects, which may be due to targeting of the constitutive proteasome in these tissues. In contrast, by selectively inhibiting the 20S, it may be possible to maintain antmyeloma and antitymoma efficacy while reducing these toxicities, thereby increasing the therapeutic index.

In this work, we describe the identification of a series of immunoproteasome-specific inhibitors (IPSIs) using an in vitro screen, and characterization of a lead compound, IPSI-001, which showed the greatest selectivity between proteasome variants. IPSI-001 induced cell death preferentially in 20S-containing cells in a dose-dependent fashion through activation of both intrinsic and extrinsic apoptotic pathways. This agent also induced apoptosis in patient-derived myeloma samples, as well as samples from patients with other hematologic malignancies. Importantly, we found that IPSI-001 was able to overcome resistance not only to conventional chemotherapeutics, but also to bortezomib. Although this first generation of IPSIs in a peptidyl-aldehyde backbone has lower potency, they will be useful for proof-of-principle studies, and can be used as a backbone upon which other chemistries can be added, such as boronic acids, to enhance their potency further. Taken together, these data provide a rationale for further study of IPSIs as possible anticancer drugs, especially in the myeloma setting.

Methods

Cell models and cell culture

RPMI 8226, ANBL-6, KAS-6/1, Sup-B8, 8226.Dox40, 8226.LR5, 8226.BR, MM1.S, MM1.R, peripheral blood mononuclear cells (PBMCs), and patient-derived cells were cultured in RPMI 1640 with 2 mM l-glutamine (Invitrogen, Carlsbad, CA). SK-N-MC, HeLa, BT-474, HT-29, and Hs294T cells were grown in DMEM containing l-glutamine and 110 mg/L sodium pyruvate (Invitrogen). SK-N-MC cells were further supplemented with 1× MEM nonessential amino acids. Human pancreatic carcinoma cells (HPACs) were cultured in a 1:1 mixture of Dulbecco modified Eagle and Ham F12 medium containing 1.2 g/L sodium bicarbonate, 2.5 mM l-glutamine, 15 mM HEPES, and 0.5 mM sodium pyruvate supplemented with 0.002 mg/mL insulin, 40 mg/mL hydrocortisone, and 10 mg/mL epidermal growth factor. Single donor human umbilical vein endothelial cells (HUVECs) were maintained with endothelial cell growth medium (PromoCell, Heidelberg, Germany). All cell lines except HUVECs were supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen) and maintained in 5% CO2 at 37°C. Interleukin-6 (IL-6)–dependent cells and purified plasma cells from patients were supplemented with 1 ng/mL IL-6 (R&D Systems, Minneapolis, MN). Patient samples were collected under a protocol approved by the University of North Carolina at Chapel Hill Institutional Review Board. Informed consent was obtained in accordance with the Declaration of Helsinki. Mononuclear cells from bone marrow aspirates or peripheral blood were isolated by density gradient centrifugation following Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ). Malignant cells were then isolated by immunomagnetic bead positive selection in a Midi magnetic-sorting (FACS). Drug-specific apoptosis was calculated as follows: [(% live in control − % live in treated)/% live in control]. Changes in the mitochondrial transmembrane potential were determined using the JC-1 dye (Invitrogen). All of these assays were performed as described previously, and according to the manufacturer’s specifications. In some cases, colorimetric substrates (R&D Systems) were used to examine caspase activation initially following the same protocol as the fluorogenic assays, except samples were then read in a multilabel plate reader (Victor 3V; Perkin-Elmer, Waltham, MA) at 405 nm. Results were expressed as fold activation over the vehicle control.

Results

IPSI-001 inhibits the immunoproteasome

To identify potentially isoform-specific proteasome inhibitors, the 20S and 20S, were purified to homogeneity from pituitary and
addition of the VS-L3-AHx3-dansyl reagent that binds to all unoccupied catalytic subunits. Protein extracts were then separated by denaturing gel electrophoresis and probed by autoradiography. Subunit identifications were made based on the known electrophoretic migration patterns of immunoproteasome and constitutive proteasome subunits (Figure 1B left panel). Similarly, in ANBL-6 myeloma spleen tissues, respectively. These preparations were then used to screen a panel of rationally designed peptidyl-aldehyde inhibitors using substrates specific for the ChT-L and C-L activities. The peptidyl-aldehyde version of bortezomib, Z-FL-CHO, showed K\textsubscript{i}'s of 2.1 and 5.55 \textmu M against the ChT-L activity of the 20S and 20Si proteasomes, respectively (Table 1). By increasing the hydrophobicity of the amino acid in the P1, or C-terminal position, however, greater selectivity could be achieved for the immunoproteasome, in that inhibitory potency was maintained for the immunoproteasome, but decreased for the constitutive proteasome. This was most notable in the case of carbobenzoxy-leucyl-norleucinal (Z-LnL-CHO, or IPSI-001; Figure 1A), which showed a 100-fold preference for the immunoproteasome, with a K\textsubscript{i} of 1.03 \textmu M against the ChT-L 20S, activity, compared with 105 \textmu M against the constitutive proteasome (Table 1). IPSI-001 also had a preference for the branched chain amino acid preferring activity of the immunoproteasome, with a K\textsubscript{i} of 1.45 \textmu M compared with 239 \textmu M for the constitutive proteasome (Table 1).

To study the binding characteristics of IPSI-001, the purified constitutive proteasome and immunoproteasome, as well as ANBL-6 myeloma cells, were exposed to increasing concentrations of this inhibitor. The purified immunoproteasome was then exposed to [\textsuperscript{14}C]-3,4-dichloroisocoumarin, whereas cells were exposed to vinyl-sulfone-LLL-AHx3-dansyl, both of which bind available proteasome active sites. Protein extracts were then separated by electrophoresis, and subjected either to autoradiography for the former, or to Western blotting with an antidansyl antibody for the latter. Preincubation of purified immunoproteasomes with IPSI-001 prevented subsequent binding of the radioactive probe only to subunit 1i, without an impact on 2i or 5i, (Figure 1B right panel), and no binding was seen to constitutive proteasome subunits (Figure 1B left panel). Similarly, in ANBL-6 myeloma cells, exposure to IPSI-001 resulted in a robust inhibition of both ChT-L and C-L activities, with a Ki of 1.03 \textmu M for ChT-L 20Si (Table 1).

**Table 1. Inhibitory potency of a panel of peptidyl-aldehydes against proteasome preparations**

<table>
<thead>
<tr>
<th>Inhibitor/activity</th>
<th>Immunoproteasome, K\textsubscript{i} (\textmu M)</th>
<th>Constitutive proteasome, K\textsubscript{i} (\textmu M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z-LLL-CHO (MG-132)</td>
<td>5.1 ± 0.9 (6)</td>
<td>6.9 ± 0.84 (6)</td>
</tr>
<tr>
<td>Z-FL-CHO (bortezomib-aldehyde)</td>
<td>2.1 ± 0.29 (9)</td>
<td>5.55 ± 0.47 (6)</td>
</tr>
<tr>
<td>Z-LnL-CHO (IPSI-001)</td>
<td>1.03 ± 0.17 (3)</td>
<td>105 ± 1.3 (3)</td>
</tr>
<tr>
<td>BrAAP</td>
<td>1.45 ± 0.15 (8)</td>
<td>239 ± 14 (6)</td>
</tr>
<tr>
<td>Z-FF-CHO (IPSI-002)</td>
<td>4.0 ± 0.27 (6)</td>
<td>56 ± 4.4 (3)</td>
</tr>
<tr>
<td>BrAAP</td>
<td>1.46 ± 0.38 (9)</td>
<td>NI</td>
</tr>
<tr>
<td>Z-hFF-CHO (IPSI-003)</td>
<td>2.74 ± 0.33 (6)</td>
<td>40*</td>
</tr>
<tr>
<td>BrAAP</td>
<td>3.19 ± 0.11 (3)</td>
<td>NI</td>
</tr>
<tr>
<td>Z-LF-CHO (IPSI-004)</td>
<td>5.6 ± 0.2 (3)</td>
<td>154*</td>
</tr>
<tr>
<td>BrAAP</td>
<td>4.07 ± 0.17 (3)</td>
<td>NI</td>
</tr>
<tr>
<td>Z-AF-CHO (IPSI-005)</td>
<td>24 (2)</td>
<td>380 (2)</td>
</tr>
<tr>
<td>BrAAP</td>
<td>24 (2)</td>
<td>NI*</td>
</tr>
</tbody>
</table>

Dixon plots were used to obtain K\textsubscript{i} values. Assays were carried out at 3 substrate concentrations and at 6 different inhibitor concentrations without preincubation of the enzyme with inhibitors, and the number of determinations is shown in parentheses. Substrate concentrations were 0.5 to 4.0 mM for the ChT-L activity using Z-GGF-pAB. Standard single-letter abbreviations are used for amino acid residues where applicable. ChT-L indicates chymotrypsin-like activity; BrAAP, branched-chain amino acid preferring; H, homophenylalanine; IC\textsubscript{50}, concentration inducing 50% target inhibition; IPSI, immunoproteasome-specific inhibitor; Ki, inhibitory constant; nL, norleucinal; pAB, para-amino-benzoate; Z, carbobenzoxy; and NI, not inhibited.*IC\textsubscript{50} instead of Ki.

**Figure 1. IPSI-001 inhibits the immunoproteasome.** (A) Chemical structure of IPSI-001. (B) Competitive binding experiment to determine subunit binding profile of IPSI-001 in purified proteasomes from bovine pituitaries (20S) and spleen (20Si). Purified proteasomes were incubated with 10 or 50 \mu M IPSI-001 or vehicle (Veh) for 20 minutes, and then [\textsuperscript{14}C]-3,4-dichloroisocoumarin was added for an additional 30 minutes. Proteasomes were then separated by denaturing gel electrophoresis and the binding profile was identified using autoradiography. Subunit identifications were made based on the known electrophoretic migration patterns of immunoproteasome and constitutive proteasome subunits. (C) Competitive binding experiment to determine the subunit binding profile of IPSI-001 in ANBL-6 cells. Cells were treated for 4 hours with IPSI-001, followed by addition of the VS-L3-AHx3-dansyl reagent that binds to all unoccupied catalytic subunits. Protein extracts were then separated by denaturing gel electrophoresis and probed with Western blotting using an antidansyl antibody to visualize binding patterns. Antitubulin was used as a loading control and anti-p11 was used to confirm the relative position of p11. (D) In vitro assay for the 3 major catalytic activities of the proteasome in ANBL-6 cell lysates (5 \mu g) exposed to increasing concentrations of IPSI-001 in triplicate. Representative data are shown as the mean plus or minus standard deviation (SD) from 3 independent experiments. *P < .05 for proteasome inhibitory activity over control. (E) Western blot analysis of the accumulation of polyubiquitinated proteasome substrates in response to 50 \mu M IPSI-001 treatment in ANBL-6 cells over a period of 24 hours.
cells, which expressed a mixture of the 2 proteasome isoforms, IPSI-001 binding occurred exclusively to β1, (Figure 1C), with no binding to other immunoproteasome or constitutive proteasome subunits.

The consequences of binding of IPSI-001 to proteasome function were studied using ANBL-6 extracts and substrates specific for the ChT-L, T-L, and C-L activities. Low concentrations of IPSI-001 resulted in inhibition of the ChT-L and C-L activities, with sparing of the T-L function (Figure 1D). Increasing concentrations of IPSI-001 provided a further, dose-dependent, decrease in ChT-L activity, though a plateau was reached in C-L activity where concentrations greater than 10 μM produced little additional inhibition. Finally, inhibition of the T-L activity was seen as well, though this occurred only at some of the highest concentrations tested. To examine the impact of immunoproteasome inhibition on cellular protein turnover, Western blotting was performed to examine ubiquitin-protein conjugate levels. Consistent with a role for the immunoproteasome in housekeeping-associated proteolytic functions, IPSI-001 induced a rapid increase in conjugates at 8 hours and lasting up to 24 hours (Figure 1E).

**Cytotoxic and proapoptotic impact of IPSI-001**

Nonspecific proteasome inhibitors such as bortezomib and carfilzomib that target both the constitutive and immunoproteasomes inhibit cellular proliferation and induce apoptotic cell death. To assess whether inhibition of the 20S, was by itself sufficient to induce similar effects, ANBL-6 cells were exposed to IPSI-001. This reduced the viability of ANBL-6 (Figure 2A) in a dose-dependent fashion within a brief, 24-hour exposure time with a half-maximal inhibitory concentration (IC50) of 30.6 μM, compared with that of bortezomib at 7.2 nM. Reduction in viability was accompanied by the induction of apoptosis, as measured by an increased content of annexin V–positive RPMI 8226 cells (Figure 2B), and by apoptotic DNA fragmentation in ANBL-6 cells (Figure S1A, available on the Blood website; see the Supplemental Materials link at the top of the online article). IPSI-001’s cytotoxic activity was compared with other proteasome inhibitors, such as epoxomicin and lactacystin, which are structurally similar to carfilzomib and NPI-0052, respectively (Figure S1B). As expected, IPSI-001 had an IC50 of 30.1 μM, whereas that of bortezomib was 5.8 nM.

Bortezomib and carfilzomib induce programmed cell death by activating both the intrinsic apoptotic pathway mediated by caspase-9, and the extrinsic pathway mediated by caspase-8–dependent signaling, which then converge on a common effector, caspase-3. We examined whether IPSI-001 also exerted its ant apoptotic effect through activation of intrinsic and extrinsic caspase pathways38 and found that dual caspase-8 and -9 activation was seen in a time-dependent fashion as early as after 4 hours (Figure 2C), which then induced caspase-3 activity. Other consequences of immunoproteasome inhibition included cleavage of PARP (Figure 2D), and depolarization of the trans-mitochondrial membrane potential (Figure S2).

Several mechanisms contribute to the proapoptotic effects of bortezomib, including suppression of nuclear factor kappa B by stabilization of its inhibitor IκB, accumulation of proapoptotic Bax, and activation of c-Jun N-terminal kinase (JNK)39,41 To evaluate the impact of IPSI-001 on these pathways, RPMI 8226 cells were treated with 25 or 50 μM IPSI-001 for 24 hours. Bax and IκBα levels were observed as early as 4 hours later (Figure 2E). Similarly, activation of JNK was also seen (Figure 2F), suggesting that immunoproteasome-specific inhibitors have comparable mechanisms of action as do current nonspecific inhibitors.

**Preferential activity of IPSI-001 in immunoproteasome-containing cells**

One of the promising aspects of IPSIs is that they should relatively spare cells expressing predominantly constitutive proteasomes. To evaluate this hypothesis, lysates from a panel of cell lines representing solid tumors that predominantly
Peripheral neuropathy is one toxicity of bortezomib against which there is no prophylaxis, and for which only symptomatic care and dose reduction or discontinuation is recommended. SK-N-MC cells, which are derived from an Askin tumor representing primitive neuroectodermal tissue, and are used to model neurotoxic drug effects, were studied. Bortezomib induced a significant increase in caspase-3 activity in these cells, which was comparable with that following exposure to paclitaxel, another neurotoxic drug (Figure 3C). In contrast, IPSI-001 to some extent spared SK-N-MC cells, even at concentrations that had induced almost complete inhibition of the ChT-L activity in hematologic tumor cells. This was reflected by a much lower extent of induction of caspase-3 activity by IPSI-001. Although studies have not been done to directly correlate proteasome inhibitor-mediated neurotoxicity in these cells, these data should give an indication of the probable effect in neural cells. To further assess the impact of IPSI-001 on primary cells, human umbilical vein endothelial cells (HUVECs) were treated with either bortezomib or IPSI-001. A slight decrease in the viable cell population of approximately 10% was observed in HUVECs treated with IPSI-001 at concentrations up to 50 μM (Figure 3D). However, HUVECs incubated with bortezomib had approximately 75% cell death at concentrations higher than 25 nM. Finally, IPSI-001 activity against peripheral blood mononuclear cells (PBMCs) was investigated, and a dose-dependent decrease in cellular viability was observed similar to that after bortezomib exposure (Figure 3E). Together, these findings suggest that IPSIs may have an improved toxicity profile, with a lesser impact on proteasome function and cellular viability in nonhematopoietic tissues than bortezomib, but may induce similar cytopenic effects.
Effect of IPSI-001 in patient-derived samples

The activity of IPSI-001 against MM cell lines suggested that it could be active against primary plasma cells as well. Consistent with the previous in vitro data, IPSI-001 strongly reduced the ChT-L–like activity and modestly reduced C-L activity at low doses (Figure 4A). At higher IPSI-001 concentrations, further ChT-L inhibition was achieved, the C-L activity reached a plateau, and significant T-L inhibition was seen only at the highest drug levels. We then examined whether IPSI-001 had antiproliferative effects against purified patient plasma cells. All of the patient samples showed sensitivity to IPSI-001 treatment for 24 hours, with dose-dependent increases in the live cell population, even in samples from patients with poor-risk disease harboring chromosome 13 deletions (Figure 4B). To confirm that this decrease was due to induction of apoptosis, flow cytometric analysis using annexin V staining was performed, and showed a dose-dependent increase in programmed cell death (Figure 4C). These experiments were performed on purified CD138⁺ plasma cells, and the effect of IPSI-001 on other clonal subsets of marrow-derived cells is not yet known.

In addition to activity against MM, bortezomib is preclinically active against other hematologic malignancies, so we also sought to examine the impact of IPSI-001 on other models. To that end, purified samples from patients with diffuse large B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) were treated with 50 μM IPSI-001 for 24 hours, followed by evaluations for viability (Figure 4D). All disease types showed evidence of some level of susceptibility to IPSI-001–induced cell death. One exception was a patient with prolymphocytic leukemia (CLL-02), a variant of CLL that is generally more aggressive and less responsive to treatment that, like one myeloma patient sample (MM-17, Figure 4B), showed only a slight response. As was the case for the plasma cell samples, exposure to IPSI-001 in 2 patient CLL isolates resulted in activation of apoptosis (Figure 4E,F).

IPSI-001 overcomes chemotherapy resistance and synergizes with dexamethasone

Novel agents that can overcome chemoresistance to other drugs may have greater potential for clinical antitumor activity, and we therefore studied IPSI-001 in several drug-resistance models. RPMI 8226 wild-type cells were compared with their doxorubicin (Dox40)–resistant, melphalan (LR5)–resistant, and bortezomib-resistant (BR) counterparts, and MM1 dexamethasone-sensitive (S) cells were compared with dexamethasone-resistant (R) cells. Doxorubicin- and melphalan-resistant clones did show some decreased sensitivity to IPSI-001, especially at lower doses (Figure 5A), suggesting the possibility of some cross-resistance. However, higher concentrations of IPSI-001 induced substantial apoptosis (Figure 5A) and DNA fragmentation (Figure 5B). Dexamethasone-resistant MM1.R cells showed comparable responses...
Figure 5, IPSI-001 is able to overcome chemotherapy resistance. (A) Drug-free for at least 48 hours; doxorubicin-, melphalan-, and bortezomib-resistant RPMI 8226; and dexamethasone-sensitive and resistant MM1 multiple myeloma cell lines were exposed to increasing doses of IPSI-001 for 24 hours in duplicate, followed by determination of apoptotic cell populations using dual annexin V/TOPRO-3 staining. The data shown are the mean plus or minus SD. *P < 0.05 compared with vehicle control. (B) ANBL-6.wt and ANBL-6.BR were compared for their sensitivity to IPSI-001 after a 24-hour exposure using WST-1 proliferation assay. The data shown are the mean plus or minus SD from experiments performed in triplicate. (C) Purified CD138+ plasma cells from patient samples were treated with 25 and 50 µM IPSI-001 for 24 hours, and the effects on cell viability were examined in triplicate. Cytogetic studies showed that MM-33 had a chromosome 13 deletion and MM-38 had a chromosome 9 deletion and trisomy 11, whereas the MM-42 sample was not evaluated. The data shown are the mean plus or minus SD. (E) RPMI 8226 cell lines resistant to doxorubicin, melphalan, and bortezomib were treated with the calpain inhibitor E64d and analyzed for annexin V staining by flow cytometry. Representative results from 2 independent experiments are shown as the mean plus or minus SD.

to IPSI-001 as the dexamethasone-sensitive MM1.S cells (Figure 5B). Our group has also developed bortezomib-resistant (BR) myeloma cell lines that show significantly decreased sensitivity to bortezomib (Figure S4).10 Notably, and in contrast to the previous data, 8226.BR cells were even more sensitive to IPSI-001 at lower doses than their wild-type counterparts, supporting the lack of any cross-resistance. The latter possibility was also studied in the independently derived, bortezomib-resistant ANBL-6.BR cells, and compared with wild-type cell populations. Comparable decreases in viable cell populations were found in both ANBL-6.wt and ANBL-6.BR cells after exposure to IPSI-001 (Figure 5C). Importantly, plasmacytes from 3 bortezomib-refractory patients all remained sensitive to 50 µM IPSI-001 and to a higher degree than comparable 10-nM bortezomib exposure, with no significant resistance found even in MM-33, a patient with chromosome 13 deletion (Figure 5D). Lastly, to rule out the possibility that it was the ability of IPSI-001 to inhibit calpains that allowed it to overcome resistance, E64d was again used as a control. Less than 20% apoptosis was observed in all cell lines tested, including wild-type cells (Figure 5E), despite the use of inhibitor levels that were 20-fold more potent than those of IPSI-001. These findings again support the assertion that it is the ability of IPSIs to target the immunoproteasome that is responsible for their activity.

Antimyeloma agents are often used in combinations to enhance their antitumor activity, and addition of dexamethasone to bortezomib is one strategy that has shown improved efficacy.18 To determine whether IPSI-001 works in concert with dexamethasone, ANBL-6 cells were treated simultaneously with both drugs for 48 hours. Compared with dexamethasone or IPSI-001 alone, the combination demonstrated a greater antiproliferative effect (Figure S5). Moreover, statistical analysis indicated that a moderate to high degree of synergy was present between the 2 drugs at most concentrations tested (Table S1).

Discussion

Multiple myeloma remains an incurable disease that almost invariably relapses after initial therapy, and though subsequent remissions can be achieved, they typically grow shorter with each successive line of chemotherapy.19 Although it is possible that the efficacy of proteasome inhibitors such as bortezomib is due to their lack of specificity for different proteasome isoforms, it is also likely that this broad inhibitory activity may contribute to the induction of treatment-emergent neuropathy, which can be dose limiting. This led us to consider that targeting the 20S, which is highly expressed in hematopoietic tissues and contains 3 different proteolytic subunits compared with the constitutive proteasome, could provide efficacy with decreased toxicity. Here, we report the identification of IPSIs that relatively spare the 20S, and the characterization of IPSI-001, the most potent of these agents. IPSI-001 preferentially inhibited immunoproteasome activity in vitro and in lymphoid-derived cell lines and patient-derived samples, induced extrinsic and intrinsic pathways of apoptosis, synergized with dexamethasone, and was able to overcome conventional drug resistance, as well as resistance to bortezomib itself.

IPSI-001 was identified in a screen of peptidyl-aldehyde compounds for favored ChT-L–inhibitory activity against 20S, and showed a 100-fold preference for this target over the comparable 20S activity (Table 1). In addition, IPSI-001 also exhibited 165-fold preference for the BrAAP activity of the 20S, which is
attributed to the $\beta_1$ and $\beta_1$, subunits (Table 1). Although the potency of IPSI-001 is not sufficient to warrant in vivo testing or translation into the clinic, its properties will be useful for further validation of the immunoproteasome as a target. Expression of 20S has been found predominantly in immune tissues, but lower levels have also been noted in the brain, intestinal epithelium, liver, and ocular lens. In the latter case, however, expression seems to be related to specific disease states leading to production of inflammatory cytokines known to induce 20S, subunits, suggesting that under normal conditions these would predominantly contain 20S. Moreover, peptide-based drugs such as bortezomib do not pass through the blood-brain barrier, implying that central nervous system toxicity would be unlikely with IPSIs as well. This leaves intestinal epithelium as an area of concern for toxicity based on the known expression profiles, but our studies of cell lines derived from such tissues (Figure S3) showed a predominant expression of 20S. Taken together, these findings suggest that IPSIs may indeed have a modest systemic toxicity profile, though they may well retain the hematologic toxicity of agents such as bortezomib, or perhaps even exceed it based on the increased cell death observed in PBMCs treated with IPSI-001 (Figure 3E). Once clinically relevant IPSIs are developed, therefore, it will be important to closely evaluate their tissue distribution and proteasome binding. In addition, studies correlating the level and type of some binding. In addition, studies correlating the level and type of important for cell motility and cell cycle progression that play roles in necrosis and apoptosis in some cell line models. To rule out the possibility that calpain inhibition was responsible for the induction of apoptosis by IPSI-001 (Figure 3B), as well as its ability to overcome chemotherapy resistance (Figure 5D), we used the sulfhydryl protease inhibitor E64d as a control. These studies showed that calpain suppression was not sufficient to accomplish either of these outcomes by itself, and studies combining bortezomib with E64d showed that this approach did not overcome bortezomib resistance (not shown). In addition, some of the IPSIs we have identified are longer than dipeptides, making them less inhibitory for calpains, and these too overcome resistance (not shown). Ultimately, however, since peptidyl-aldehydes can react with free sulfhydryl groups, the role of calpain inhibition in these processes will be completely ruled out only with peptides based on other chemistries that reduce binding to sulfhydryl groups, such as boronic acids. It is also notable that recent data point to an increase in calpain activity in proteasome-inhibited cells, as well as in a cisplatin-resistant melanoma cell line. These findings suggest that IPSI-001, or other calpain inhibitors, may prove to be useful in combination therapies where the dual calpain/20Si inhibitory IPPI-001, or other calpain inhibitors, may prove to be useful in passing through the blood-brain barrier, implicating that central nervous system toxicity would be unlikely with IPSIs as well. This leaves intestinal epithelium as an area of concern for toxicity based on the known expression profiles, but our studies of cell lines derived from such tissues (Figure S3) showed a predominant expression of 20S. Taken together, these findings suggest that IPSIs may indeed have a modest systemic toxicity profile, though they may well retain the hematologic toxicity of agents such as bortezomib, or perhaps even exceed it based on the increased cell death observed in PBMCs treated with IPSI-001 (Figure 3E). Once clinically relevant IPSIs are developed, therefore, it will be important to closely evaluate their tissue distribution and proteasome binding. In addition, studies correlating the level and type of important for cell motility and cell cycle progression that play roles in necrosis and apoptosis in some cell line models. To rule out the possibility that calpain inhibition was responsible for the induction of apoptosis by IPSI-001 (Figure 3B), as well as its ability to overcome chemotherapy resistance (Figure 5D), we used the sulfhydryl protease inhibitor E64d as a control. These studies showed that calpain suppression was not sufficient to accomplish either of these outcomes by itself, and studies combining bortezomib with E64d showed that this approach did not overcome bortezomib resistance (not shown). In addition, some of the IPSIs we have identified are longer than dipeptides, making them less inhibitory for calpains, and these too overcome resistance (not shown). Ultimately, however, since peptidyl-aldehydes can react with free sulfhydryl groups, the role of calpain inhibition in these processes will be completely ruled out only with peptides based on other chemistries that reduce binding to sulfhydryl groups, such as boronic acids. It is also notable that recent data point to an increase in calpain activity in proteasome-inhibited cells, as well as in a cisplatin-resistant melanoma cell line. These findings suggest that IPSI-001, or other calpain inhibitors, may prove to be useful in combination therapies where the dual calpain/20S inhibitory effect is ChT-L > C-L > T-L. We found that IPSI-001 bound potently and specifically to the $\beta_1$, subunit (Figure 1B,C) yet had an inhibitory profile similar to bortezomib (Figure 1D). Previous reports have generally attributed proteolytic activities of the 20S, catalytic subunits to their 20S counterparts, a model in which $\beta_5$, should encode the ChT-L activity. Of note, Ho et al recently reported development of a $\beta_1$, (LMP-2)–specific inhibitor that had greater growth inhibitory effects in cell populations with high $\beta_1$, expression. However, the $\beta_1$,–specific inhibitor developed by Ho et al was found to have ChT-L inhibitory activity, and the authors suggested that overlapping catalytic activities existed for the $\beta_1$, subunit. The phenomenon of simultaneous inhibition of the ChT-L activity has been reported by 2 other groups who developed constitutive $\beta_1$ inhibitors with moderate specificity whose activity was attributed to allosteric inhibition of the $\beta_5$ subunit. Lastly, a report by Kisselev et al, using a highly specific $\beta_1$ inhibitor, demonstrated that the dual ChT-L and C-L inhibitory properties were due to (1) the $\beta_1$ inhibitor binding and inhibiting the C-L activity; (2) binding of the $\beta_1$ inhibitor to a noncatalytic regulatory site that inhibits the ChT-L activity; and (3) $\beta_1$ inhibitors allosterically stimulating the T-L activity. Given the similar inhibitory profiles of IPSI-001 and the inhibitor developed by Ho et al, we postulate that these $\beta_1$ inhibitors also bind the noncatalytic, regulatory subunit proposed by Kisselev et al that is present in both 20S and 20T, proteasomes. This possibility is further supported by increased binding potential of IPSI-001 to the $\beta_1$, subunit in relation to BrAAP activity (Table 1).

In general, plasma cell isolates from patients responded to exposure to IPSI-001 (Figure 4B), but in one patient sample, MM-17, a very modest effect was observed. This patient was found to have harbored disease with deletion of chromosome 13, which is a poor prognostic marker for myeloma, but one that typically responds well to bortezomib. However, deletions of chromosome 13 were also present in samples MM-24, MM-26, MM-33, MM-40, and MM-41, which did respond well. In addition, patient MM-17 had received 2 prior therapies, including bortezomib, and initially responded to therapy but had progressive disease off treatment. Three patients were clinically refractory to bortezomib at the time their cells were isolated (MM-33, MM-38, and MM-42), yet remained sensitive to IPSI-001. Interestingly, MM-33 and MM-42 had plasma cell leukemia that is typically an aggressive myeloma variant, but both responded well to IPSI-001.

In conclusion, our data indicate that the immunoproteasome is a rational target for anticancer therapy in MM. Agents based on IPSI-001, or some of the other IPSIs that have been identified, which would have enhanced potency without losing their specificity, should strongly induce apoptosis in MM and other hematologic malignancies. Moreover, they should relatively spare other tissues not expressing the immunoproteasome, unlike the current generation of nonspecific proteasome inhibitors, possibly thereby providing an improved therapeutic index. The latter could allow for more chronic dosing that could prove useful not just in cancer, but in treating other disorders such as autoimmune diseases and graft rejection that rely in part on antigen presentation that is processed through the immunoproteasome.

Acknowledgments

R.Z.O., a Leukemia & Lymphoma Society Scholar in Clinical Research, and a Jefferson Pilot fellow in Academic Medicine, acknowledges support from the Leukemia & Lymphoma Society (White Plains, NY: 6096-07), the Multiple Myeloma Research...
Foundation (Norwalk, CT), the Greensboro chapter of Golfers Against Cancer (Greensboro, NC), and the National Cancer Institute (R01-CA102278). D.J.K. was supported by the American Cancer Society (Atlanta, GA; PF-07-112-01-CCD 01).

Authorship

Contribution: D.J.K. designed and performed the majority of the research and wrote the manuscript; M.O. performed the initial screen of the peptide aldehydes and the dichloroisocoumarin competitive binding assay; S.A.H. and Q.C. helped with flow cytometric experiments; R.Z.O. and P.M.V. consented patients and obtained their samples; Q.C. and P.M.V. were essential for helping with patient sample purifications; R.Z.O. supervised all the research completed herein and offered valuable suggestions and manuscript editing.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Robert Z. Orlowski, The University of Texas M. D. Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Unit 429, Houston, TX 77030-4009; e-mail: rorlowsk@mdanderson.org.

References


Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Deborah J. Kuhn, Sally A. Hunsucker, Qing Chen, Peter M. Voorhees, Marian Orlowski and Robert Z. Orlowski